Antiviral chemotherapeutic agents against respiratory viruses: Where are we now and what's in the pipeline?

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 3, 2004, Pages 197-203

  Brooks, Megan J ^a,b   Sasadeusz, Joseph J ^b   Tannock, Gregory A ^a  

^a RMIT UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Antiviral agents; Neuraminidase inhibitors; Respiratory viruses

Indexed keywords

AMANTADINE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CELL ADHESION MOLECULE; OSELTAMIVIR; PROTEINASE; RIBAVIRIN; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; VIRUS ENZYME; ZANAMIVIR;

ANTIVIRAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HOST CELL; HUMAN; INFECTION PREVENTION; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS; STATISTICAL SIGNIFICANCE; TRANSCRIPTION TERMINATION; TRANSLATION REGULATION; VIRUS CAPSID; VIRUS INFECTION; VIRUS INHIBITION;

EID: 1942468738     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200405000-00009     Document Type: Review

References (88)

1. Monto AS: The role of antivirals in the control of influenza. Vaccine 2003, 21:1796-1800. An excellent article providing an understanding of the issues around the use of antiviral drugs for influenza virus infections.
2. Fendrick A, Monto A, Nightengale B, et al.: The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003, 163:487-494.
3. White D, Fenner F: Medical Virology, edn 4. Sydney: Academic Press; 1994.
4. Greenberg S: Respiratory consequences of rhinovirus infection. Arch Intern Med 2003, 163:278-284.
5. van den Hoogen B, de Jong JC, Groen J, et al.: A newly discovered human metapneumovirus isolated from young children with respiratory tract disease. Nat Med 2001, 7:719-724.
6. Peiris J, Lai S, Poon L, et al.: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet [serial online] April 2003:8.
7. Poutanen SM, Low DE, Henry B, et al.: Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003, 348:1995-2005.
8. Tsang KW, Ho PL, Ooi GC, et al.: A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1977-1985.
9. Fedson D, Hirota Y, Shin H, et al.: Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997, 15:1506-1511.
10. Hemming VG, Prince GA, Groothuis JR, et al.: Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995, 8:22-33.
11. De Clercq E: Antiviral drugs: current state of the art. J Clin Virol 2001, 22:73-89.
12. Guerguerian A-M, Gauthier M, Lebel MH, et al.: Ribavirin in ventilated respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 1999, 160:829-834.
13. Bridges C, Harper S, Fukuda K, et al.: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control 2003, April:25.
14. Pinto L, Holsinger L, Lamb R: Influenza virus M2 protein has ion channel activity. Cell 1992, 69:517-528.
15. Hay A: The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992, 3:21-30.
16. Hayden FG, Cote KM, Douglas RG: Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 1980, 17:865-870.
17. Tominack R, Hayden F: Rimantidine hydrochloride and amantadine hydrochloride use in influenza A infections. Infect Dis Clin North Am 1987, 1:459-478.
18. Dolin R, Reichman R, Madore H, et al.: A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982, 307:580-584.
19. Jefferson T, Demicheli V, Deeks J, Rivetti D: Amantadine and rimantadine for preventing and treating influenza A in adults (Cochrane Review). Cochrane Database of Systematic Reviews 2002, 3:CD001169.
20. Meissner HC: Antiviral drugs for prophylaxis and treatment of influenza; 2001.
21. Van Voris L, Betts R, Hayden F, et al.: Successful treatment of naturally occurring influenza A/USSR/77 H1N1. J Am Med Assoc 1981, 245:1128-1131.
22. Hayden F, Monto A: Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986, 29:339-341.
23. Masuda H, Suzuki H, Saito R, et al.: Incidence of rimantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan. Microbiol Immunol 2000, 44:833-839.
24. Colman P, Varghese J, Laver W: Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983, 303:41-44.
25. Varghese J, Laver G, Colman P: Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983, 303:35-80.
26. von Itzstein M, Wu W, Kok G, et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
27. MIST. Management of Influenza in the Southern Hemisphere Trialists: Randomised trial of efficacy and safety of inhaled zanamivir in the treatment of influenza A and B virus infections. Lancet 1998, 352:1877-1881.
28. Monto A, Fleming D, Henry D, et al.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infection. J Infect Dis 1999, 180:254-261.
29. Boivin G, Goyette N, Hardy I, et al.: Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000, 181:1471-1474.
30. Hedrick J, Barzilai A, Behre U, et al.: Zanamivir for treatment of symptomatic influenza A and B infections in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000, 19:410-417.
31. Lalezari J, Campion K, Keene O, et al.: Zanamivir for treatment of influenza A and B in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001, 161:212-217.
32. Monto A, Robinson D, Herlocher M, et al.: Zanamivir in the prevention of influenza among healthy adults, a randomised controlled trial. JAMA 1999, 282:31-35.
33. FDA. Relenza (zanamivir). In.: FDA/CDER Web site accessed 4 August, 2003; 2001.
34. Williamson J, Pegram P: Respiratory distress associated with zanamivir. N Engl J Med 2000, 342:661-662.
35. MMWR: Use of neuraminidase inhibitors for treatment of influenza A and B infections. Morbid Mortal Weekly Rep 1999, 48:1-9.
36. Kim C, Lew W, Williams M, et al.: Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997, 119:681-690.
37. Roche: Tamiflu™ (oseltamivir phosphate) capsules. In: Product Information. Nutley, NJ: Roche Laboratories; 2000.
38. Mendel DB, Tai CY, Escarpe PA, et al.: Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998, 42:640-646.
39. Hayden F, Rollins B: In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses. In: 10th International Conference on Antiviral Research. Atlanta, GA; 1997:A86.
40. Leneva I, Roberts N, Govorkova E, et al.: The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000, 48:101-115.
41. Nicholson K, Aoki F, Osterhaus A, et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: A randomized controlled trial. Lancet 2000, 355:1845-1850.
42. Treanor JJ, Hayden FG, Vrooman PS, et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000, 283:1016-1024.
43. Kaiser L, Wat C, Mills T, et al.: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
44. Whitley RJ, Hayden FG, Reisinger KS, et al.: Oral oseltamivir treatment of influenza in children. Paediatr Infect Dis J 2001, 20:127-133.
45. Hayden F, Atmar R, Schilling M, et al.: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999, 341:1336-1343.
46. Welliver R, Monto A, Carewicz O, et al.: Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomised controlled trial. JAMA 2001, 285:748-754.
47. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al.: Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-Amino-Neu5Ac2en and 4-Guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996, 40:40-46.
48. Tai CY, Escarpe PA, Sidwell RW, et al.: Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998, 42:3234-3241.
49. McKimm-Breschkin J, Sahasrabudhe A, Blick T, et al.: Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998, 72:2456-2462.
50. Blick T, Tiong T, Sahasrabudhe A, et al.: Generation and characterisation of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995, 214:475-484.
51. Gubareva L, Matrosovich M, Brenner M, et al.: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998, 178:1257-1262.
52. Ison MG, Mills J, Openshaw P, et al.: Current research on respiratory viral infections: Fourth International Symposium. Antiviral Res 2002, 55:227-278. A collection of brief reports on the recent developments of both vaccines and antivirals for respiratory virus infections, which serves as an excellent starting point for those wishing to gain an overall perspective on the area.
53. Gubareva L, Kaiser L, Matrosovich M, et al.: Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001, 183:523-531.
54. Kandel R, Hartshorn KL: Prophylaxis and treatment of influenza virus infection. BioDrugs 2001, 15:303-323.
55. Sidwell R, Huffman J, Khare G, et al.: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972, 177:705-706.
56. Crotty S, Cameron C, Andino R: Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002, 80:86-95. This paper describes the various suggested mechanisms proposed for the antiviral activity of ribavirin and adds an interesting new theory to the mix.
57. McHutchison J, Gordon S, Schiff E, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485.
58. Hall C, Walsh E, Hruska J, et al.: Ribavirin treatment of experimental respiratory syncytial virus infection. JAMA 1983, 249:2666.
59. McCormick J, King I, Webb P, et al.: Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986, 314:20-26.
60. Hall C, McBride J, Walsh EE, et al.: Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection: a randomised double-blind study. N Engl J Med 1983, 308:1443-1447.
61. Hall C, McBride J, Gala C, et al.: Ribavirin treatment of respiratory syncytial virus infection in infants with underlying cardiopulmonary disease. JAMA 1985, 254:3047-3051.
62. Moler F, Steinhart C, Ohmit S, Stidham G: Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr 1996, 128:422-428.
63. Randolph AG, Wang EE: Ribavirin for respiratory syncytial virus lower respiratory tract infection. Arch Paediatr Adolesc Med 1996, 150:942-947.
64. Collins P, Chanock R, Murphy B: Respiratory syncytial virus. In Field's Virology, edn 4. Edited by Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al. Philadelphia: Lippincott, Williams & Wilkins; 2001.
65. Chakrabarti S, Collingham K, Holder K, et al.: Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2001, 28:759-763.
66. Vujovic O, Mills J: Preventive and therapeutic strategies for respiratory syncytial virus infection. Curr Opin Pharmacol 2001, 1:497-503.
67. Wright PF, Webster RG: Orthomyxoviruses. In Field's Virology, edn 4. Edited by Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al. Philadelphia: Lippincott, Williams & Wilkins; 2001.
68. Black CP: Systematic review of the biology and medical management of syncytial respiratory virus infection. Respir Care 2003, 48:209-233. A comprehensive analysis of the respiratory disease caused by RSV and the various options for its control.
69. AAPC. American Academy of Pediatrics Committee on Infectious Diseases: reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996, 97:137-140.
70. DeVincenzo J, Hirsch R, Fuentes R, et al.: Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience. Bone Marrow Transplant 2000, 25:161-165.
71. Kinchington D, Kangro H, Jeffries DJ: Design and testing of antiviral compounds. In Medical Virology: A Practical Approach. Edited by Desselberger U. Oxford: Oxford University Press; 1997.
72. De Clercq E: Molecular targets for antiviral agents. J Pharmacol Exp Ther 2001, 297:1-10.
73. Racaniello VR: Picornaviridae: the viruses and their replication. In Field's Virology, edn 4. Edited by Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al. Philadelphia: Lippincott, Willians & Wilkins; 2001.
74. Shigeta S: Approaches to antiviral chemotherapy for acute respiratory infections. Antivir Chem Chemother 1998, 9:93-107.
75. Turner R, Wecker M, Pohl G, et al.: Efficacy of soluble ICAM-1 (sICAM) for prevention of rhinovirus infection and illness, abstract H-85. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; Washington, D.C.: American Society for Microbiology; 1997:77.
76. Douglas J, Panis M, Ho E, et al.: Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol 2003, 77:5054-5064.
77. Wyde PR, Moore-Poveda DK, O'Hara B, et al.: CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res 1998, 38:31-42.
78. Huntley C, Weiss W, Gazumyan A, et al.: RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 2002, 46:841-847.
79. Kati WM, Montgomery D, Carrick R, et al.: In vitro characterisation of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother 2002, 46:1014-1021.
80. Brouillette W, Bajpai S, Ali S, et al.: Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents. Bioorg Med Chem 2003, 11:2739-2749.
81. Honda T, Masuda T, Yoshida S, et al.: Synthesis and anti-influenza virus activity of 4-Guanidino-7-substituted-Neu5Ac2en derivatives. Bioorg Med Chem Lett 2002, 12:1921-1924.
82. Leaman D, Longano F, Okicki J, et al.: Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 2002, 292:70-77. This paper describes novel antisense technology that allows the specific cleavage RSV genomic RNA, resulting in a reduction of viral replication in vitro and in vivo.
83. Patick A, Binford S, Brothers M, et al.: In vitro antiviral activity of ruprintrivir, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999, 43:2444-2450.
84. Anand K, Ziebuhr J, Wadhwani P, et al.: Coronavirus main protease (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300:1763-1767.
85. Watanabe W, Sudo K, Sato R, et al.: Novel Anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives. Biochem Biophys Res Commun 1998, 249:922-926.
86. Sudo K, Watanabe W, Konno K, et al.: Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob Agents Chemother 1999, 43:752-757.
87. Sudo K, Konno K, Watanabe W, et al.: Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiol Immunol 2001, 45:531-537.
88. Brooks MJ: Studies with the antiviral drug arbidol [PhD thesis]. Melbourne, Australia: RMIT University; 2003.